Ticker

KAWASAKI, Japan--(BUSINESS WIRE)-- #DrugDelivery--The first patient has been dosed with 64Cu-PD-29875 in a first-in-human clinical study in patients with gastric cancer.

KAWASAKI, Japan--(BUSINESS WIRE)-- #Cancer--Completion of patient dosing in the registrational Phase 2 clinical trial of 64Cu-PSMA-I&T —a PET radiopharmaceutical targeting PSMA.

BOSTON, June 11, 2026 (GLOBE NEWSWIRE) -- Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., patient dosing has been completed in the registrational Phase 2 clinical trial for 64Cu-PSMA-I&T in Japan.

KAWASAKI, Japan--(BUSINESS WIRE)-- #AutoimmuneDisease--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”) today announced that Asahi Kasei Therapeutics (Headquarters: Chiyoda-ku, Tokyo, Japan; President: Daisuke Okajima, hereinafter “Asahi Kasei Therapeutics”), its collaboration partner, has initiated a Phase 1 clinical trial*1 of…